Our News on Newswise

Newswise: 65dcb85433e1f_fountzilasbakin.jpg

Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers

A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers.
26-Feb-2024 11:30 AM EST Add to Favorites

Novel Treatment Regimen for FLT3-Mutated Acute Myeloid Leukemia Shows Promise in Roswell Park-Led Study

Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.
8-Feb-2024 3:00 PM EST Add to Favorites

Newswise: adobestock_181431116.jpg

Roswell Park Study Defines Mechanisms Underlying Promising Precision Therapy for Pancreatic Cancer

A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer.
2-Feb-2024 1:55 PM EST Add to Favorites

Simple Blood Protein Tests Predict Which Lymphoma Patients Are Most Likely to Have Poor CAR T Outcomes

As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies.
2-Feb-2024 1:40 PM EST Add to Favorites

FL118, Drug Candidate Discovered at Roswell Park, Granted FDA Orphan Drug Status for Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.
2-Feb-2024 1:25 PM EST Add to Favorites

Newswise: 65b3f3fd2ab71_sabygeorgenewweb.jpg

Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma — With Much Faster Treatment Time

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial...
26-Jan-2024 1:05 PM EST Add to Favorites

Newswise: 656e362ed0e79_bettsholtanmallhi.jpg

Experts in Transplantation, Engineered Cells and Pediatrics Join Growing Roswell Park Cell Therapy Program

Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York...
4-Dec-2023 3:50 PM EST Add to Favorites

Newswise: 6553b40090f16_gandhikalinski2019crop.jpg

Novel Immunotherapy Approach at Roswell Park Shows Promise in Metastatic Triple-Negative Breast Cancer

A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).
14-Nov-2023 1:05 PM EST Add to Favorites


See All News

Our Experts on Newswise

Cancer-Specific Clinical Research Center: New Frontiers in Research at Roswell Park

Clinical trials are the frontier for targeted cancer drugs. Roswell Park Cancer Institute recently opened one of only a few clinical research centers in the U.S. focused exclusively on cancer. The Clinical Research Center, under the direction of...
4-Apr-2008 1:00 PM EDT

See All Experts

About

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or [email protected].

Experts

Contacts

Annie Deck-Miller
Director of Public Relations
Cancer research and treatment

annie.deck-miller@roswellpark.org

716-845-8593

Brucato Connie
Executive Assistant

constance.brucato@roswellpark.org

Heidi Findlay
Executive Director, Marketing and Communications

heidi.findlay@roswellpark.org

(716) 353-3716

Rebecca Vogt
Media Relations Specialist
Cancer

rebecca.vogt@roswellpark.org

716-845-4919

Twitter

close
0.28804